Growth Metrics

ENDRA Life Sciences (NDRA) Net Cash Flow (2016 - 2025)

ENDRA Life Sciences has reported Net Cash Flow over the past 6 years, most recently at -$2.3 million for Q4 2021.

  • Quarterly Net Cash Flow fell 167.9% to -$2.3 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2021, up 112.15% year-over-year, with the annual reading at -$2.5 million for FY2025, 723.68% down from the prior year.
  • Net Cash Flow was -$2.3 million for Q4 2021 at ENDRA Life Sciences, down from -$2.3 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $9.6 million in Q1 2021 and troughed at -$3.1 million in Q1 2020.
  • The 5-year median for Net Cash Flow is -$1.2 million (2017), against an average of $465829.0.
  • Year-over-year, Net Cash Flow plummeted 21648.18% in 2018 and then soared 39075.66% in 2020.
  • A 5-year view of Net Cash Flow shows it stood at -$1.4 million in 2017, then soared by 524.13% to $5.8 million in 2018, then tumbled by 33.17% to $3.9 million in 2019, then decreased by 11.92% to $3.4 million in 2020, then tumbled by 167.9% to -$2.3 million in 2021.
  • Per Business Quant, the three most recent readings for NDRA's Net Cash Flow are -$2.3 million (Q4 2021), -$2.3 million (Q3 2021), and -$2.8 million (Q2 2021).